The Canadian Anti-Doping Program (CADP) is the set of rules that govern doping control in Canada. Compliant with the World Anti-Doping Code and all international standards, the CADP describes how the program is carried out and details the process of results management. It also sets the education standard for values-based sport in Canada.
The CADP was revised in 2010 to stay in compliance with recent changes to the Code.
The current Canadian Anti-Doping Program is version 3.0, March 1, 2011.
The Canadian Centre for Ethics in Sport (CCES) is leading Canada’s national response to a full anti-doping rule review. Your feedback is vital to this important process. The World Anti-Doping Agency (WADA) has begun a year-long consultation on the World Anti-Doping Code and international standards, which harmonized the fight against doping for all countries and sports when they came into effect eight years ago.
We asked for Canadian sport’s contribution to an international anti-doping rule review, and the response was impressive: 69 people from national sport organizations and the public at large took the time to complete our survey. All responses and comments were analyzed and included with Canada’s national submission to the World Anti-Doping Agency (WADA). We greatly value your commitment to strengthening the fight against doping for athletes worldwide.
This concludes the first phase of the consultation on the World Anti-Doping Code. You will see further communication about this review process from the CCES during the summer of 2012. The new version of the Code and the Canadian Anti-Doping Program, based on the results of this consultation process, come into effect in January 2015.
Section 1: General Principles
There are fundamental changes coming in 2011 to the Canadian Policy Against Doping in Sport, the Federal/Provincial policy that sets the context for the jurisdiction for anti-doping in Canada. Parts of the policy that will not be carried forward will be incorporated into the CADP (Rules 1.0-1.3).
Fundamental roles and responsibilities of athletes or other persons, including athlete support personnel, will be further defined (Rules 1.0-1.3, 1.7-1.8).
Section 5: Therapeutic Use Exemption (TUE) and Medical Review Rules
There is a fundamental shift in the process for athletes who have been prescribed a prohibited medication for medically justified reasons. One group of athletes requires a Therapeutic Use Exemption (TUE) prior to being able to use a prohibited substance or method in sport. The remaining athletes can access a retroactive medical review process in the event that they undergo doping control. The intent of this approach is to clearly define who requires a TUE in advance of competition and who may meet anti-doping requirements through being followed by a licensed medical practitioner.
Section 6: Doping Control Rules
The World Anti-Doping Agency’s (WADA) Athlete Biological Passport Operating Guidelines (Rule 6.1) were incorporated, including three new annexes for the collection, transport and analytical requirements (Annex 6H-J).
Whereabouts submission dates were clarified to synchronize with ADAMS submission deadlines of January 1, April 1, July 1 and October 1 annually (Rule 6.98).
Section 7: Doping Violations and Consequences Rules
The status of an athlete or person during a period of ineligibility was clarified and expanded (Rule 7.18).
Confidentiality rules were enhanced (Rule 7.22).
The ability for additional conditions to be imposed for reprimands was added (Rule 7.43).
Rule 7.56 was expanded to add context that all anti-doping rule violations during an athlete’s career may serve relative to the determination of fault.
The initial review of adverse analytical findings and atypical findings was expanded to consider whether the finding is for a level of athlete requiring a medical review (Rule 7.63 and 7.64). The initial review process for other rule violations was expanded for the inclusion of the athlete biological passport (Rule7.65).
The process for undertaking an investigation of other anti-doping rule violations was revised. Rule 7.69 was deleted and Rules 7.70-7.71 were substantially modified.
The practice of an athlete being offered by the CCES and accepting a voluntary provisional suspension for non-analytical violations has been added (Rule 7.72 and 7.74c).
The results process for the Athlete Biological Passport has been added as Annex A in Section 7.
Section 8: Appeal Rules
The ability to appeal a decision coming from a medical review was added.
Section 9 Privacy Rules
The ability for third parties to share information with the CCES was made explicit (Rule 9.2).